You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,611,702


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,611,702
Title:TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
Abstract: The present invention provides methods for treating adverse events related to immunotherapy. More specifically, the present invention provides methods for treating the enterocolitis associated with anti-CTLA-4 antibody immunotherapy.
Inventor(s): Fischkoff; Steven (Short Hills, NJ), Lowy; Israel (Dobbs Ferry, NY), Yellin; Michael (Montclair, NJ), Yang; James Chung-Yin (Silver Spring, MD)
Assignee: Medarex, Inc. (Princeton, NJ)
Application Number:11/557,835
Patent Claims:1. A method for treating enterocolitis induced by an-anti-CTLA-4 antibody in a patient, comprising administering to the patient an amount of a TNF-.alpha. blocking agent effective to treat the enterocolitis, wherein the TNF-.alpha. blocking agent is selected from the group consisting of an anti-TNF-.alpha. antibody and a TNF receptor fusion protein.

2. The method of claim 1, wherein the anti-CTLA-4 antibody is a human sequence antibody that binds to human CTLA-4.

3. The method of claim 2, wherein the anti-CTLA-4 antibody is 10D1 (ipilimumab).

4. The method of claim 1, wherein the anti-TNF-.alpha. antibody is selected from the group consisting of infliximab, certolizumab pegol (CDP870), golimumab and adalimumab.

5. The method of claim 4, wherein the anti-TNF-.alpha. antibody is infliximab.

6. The method of claim 5, comprising administering infliximab in a single dose of about 5 mg/kg.

7. The method of claim 1, wherein the TNF-.alpha. blocking agent is administered intravenously.

8. The method of claim 1, wherein the anti-CTLA-4 antibody is for the treatment of cancer.

9. The method of claim 8, wherein the cancer is metastatic melanoma or renal cell carcinoma.

10. A method for treating enterocolitis induced by an-anti-CTLA-4 antibody in a patient, comprising administering to the patient an amount of a TNF-.alpha. blocking agent effective to treat the enterocolitis, wherein the TNF-.alpha. blocking agent is selected from the group consisting of an anti-TNF-.alpha. antibody and a TNF receptor fusion protein, wherein the enterocolitis induced by an anti-CTLA-4 antibody is refractory to steroid treatment.

11. The method of claim 10, wherein the anti-CTLA-4 antibody is a human sequence antibody that binds to human CTLA-4.

12. The method of claim 11, wherein the anti-CTLA-4 antibody is 10D1 (ipilimumab).

13. The method of claim 10, wherein the anti-TNF-.alpha. antibody is selected from the group consisting of infliximab, certolizumab pegol (CDP870), golimunab, and adalimumab.

14. The method of claim 13, wherein the anti-TNF-.alpha. antibody is infliximab.

15. The method of claim 14, comprising administering infliximab in a single dose of about 5 mg/kg.

16. The method of claim 10, wherein the TNF-.alpha. blocking agent is administered intravenously.

17. The method of claim 10, wherein the anti-CTLA-4 antibody is for the treatment of cancer.

18. The method of claim 17, wherein the cancer is metastatic melanoma or renal cell carcinoma.

19. The method of claim 1 or 10, further comprising administering an effective amount of a gut-decontaminating antibiotic to the patient.

20. The method of claim 1 or 10, wherein the TNF receptor fusion protein is etanercept.

Details for Patent 7,611,702

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 08/24/1998 ⤷  Try a Trial 2025-11-08
Immunex Corporation ENBREL etanercept For Injection 103795 11/02/1998 ⤷  Try a Trial 2025-11-08
Immunex Corporation ENBREL etanercept For Injection 103795 05/27/1999 ⤷  Try a Trial 2025-11-08
Immunex Corporation ENBREL etanercept Injection 103795 09/27/2004 ⤷  Try a Trial 2025-11-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.